Cancer NetworkOriginal article
<![CDATA[Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy]]>
RegulatoryapprovedSpaceOAR Flex SystemPositive
AI Analysis
Summary
The FDA cleared the SpaceOAR Flex System, a hydrogel spacer for prostate cancer radiotherapy, via 510(k) pathway supported by the HYDROSPACE trial.
Clinical Trial Data
Outcome Details
FDA 510(k) clearance
Importance:6/10
Sentiment:
0.80
FDA clearance510(k)prostate cancerradiotherapyhydrogel spacerHYDROSPACE trialmedical device
Related Companies
Read the original article
Published by Cancer Network on September 28, 2026 5:00 PM